Musical Chairs At Glaxo Research
Hot on the heels of Sir Paul Girolami's final departure from Glaxo, and Franz Humer's move to Roche, comes news of a major reshuffle in Glaxo's research and development management structure. Prior to this, the company's research and development was split into two groups, headed by Sir Mark Richmond and Goran Ando respectively.
Last month, Glaxo deputy chairman and chief executive Sir Richard Sykes announced that James Niedel, senior vice president of Glaxo Research and Development Ltd (Glaxo's US subsidiary) and director of the Glaxo Research Institute in North Carolina, is to be group research and development director worldwide, reporting to Sir Richard.
Under Dr Niedel will be a new organization for Glaxo's R&D, resulting in the following further appointments:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze